Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Express Scripts
Mallinckrodt
Baxter
Moodys

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ARAMCHOL

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Aramchol

Trial ID Title Status Sponsor Phase Summary
NCT00776841 A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers Completed Galmed Medical Reserch Phase 1 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1. To assess and characterize the safety and tolerability of Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B) 2. To assess the pharmacokinetics of Aramchol at the administered doses
NCT01094158 Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Beilinson Hospital, Petach Tikva,Israel Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
NCT01094158 Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Hadassah Medical Organization Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
NCT01094158 Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Hillel Yaffe Medical Center Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
NCT01094158 Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Holy Family Hospital, Nazareth, Israel Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
NCT01094158 Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Kaplan Hospital ,Rehovot,Israel Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Aramchol

Condition Name

Condition Name for
Intervention Trials
Healthy 3
Healthy Volunteers 2
Metabolic Syndrome 1
HIV 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Fatty Liver 4
Non-alcoholic Fatty Liver Disease 3
Liver Diseases 2
Metabolic Syndrome X 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Aramchol

Trials by Country

Trials by Country for
Location Trials
United States 9
Israel 4
Mexico 2
United Kingdom 2
Chile 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
California 3
Texas 2
Virginia 1
North Carolina 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Aramchol

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 4
Recruiting 3
Not yet recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Aramchol

Sponsor Name

Sponsor Name for
Sponsor Trials
Galmed Pharmaceuticals Ltd 6
Tel-Aviv Sourasky Medical Center 2
Diamond Pharma Services 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Other 33
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Moodys
McKesson
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.